No connection

Search Results

DHR vs GILD

DHR
Danaher Corporation
NEUTRAL
Price
$195.50
Market Cap
$138.36B
Sector
Healthcare
AI Confidence
85%
GILD
Gilead Sciences, Inc.
NEUTRAL
Price
$132.90
Market Cap
$164.96B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
DHR
38.94
GILD
19.6
Forward P/E
DHR
21.49
GILD
13.81
P/B Ratio
DHR
2.63
GILD
7.27
P/S Ratio
DHR
5.63
GILD
5.6
EV/EBITDA
DHR
19.57
GILD
12.4

Profitability

Gross Margin
DHR
59.23%
GILD
78.84%
Operating Margin
DHR
22.17%
GILD
37.38%
Profit Margin
DHR
14.71%
GILD
28.9%
ROE
DHR
7.05%
GILD
40.66%
ROA
DHR
4.18%
GILD
12.52%

Growth

Revenue Growth
DHR
4.6%
GILD
4.7%
Earnings Growth
DHR
12.5%
GILD
23.4%

Financial Health

Debt/Equity
DHR
0.37
GILD
1.13
Current Ratio
DHR
1.87
GILD
1.55
Quick Ratio
DHR
1.4
GILD
1.23

Dividends

Dividend Yield
DHR
0.82%
GILD
2.47%
Payout Ratio
DHR
25.45%
GILD
46.61%

AI Verdict

DHR NEUTRAL

Danaher Corporation presents a dichotomy between strong operational quality and poor valuation metrics. The deterministic baseline is weak, with a Piotroski F-Score of 4/9 (Stable) and a current price of $195.50 that significantly exceeds both the Graham Number ($91.62) and the Intrinsic Value ($129.26). While the balance sheet is exceptionally healthy with low debt/equity (0.37), the stock is trading at a steep premium. Despite a 'Strong Buy' analyst consensus and a high target price of $256.05, the bearish technical trend and insider selling suggest caution.

Strengths
Very low Debt/Equity ratio (0.37) indicating high financial solvency
Strong Gross Margins (59.23%) reflecting significant pricing power
Consistent long-term track record of earnings beats over 25 quarters
Risks
Significant overvaluation relative to Graham and Intrinsic value models
Bearish technical trend (0/100) and negative 6-month price performance
Slow organic revenue growth (4.60% YoY)
GILD NEUTRAL

GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.

Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth

Compare Another Pair

DHR vs GILD: Head-to-Head Comparison

This page compares Danaher Corporation (DHR) and Gilead Sciences, Inc. (GILD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile